A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.


Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
Fed. Cir. Flash Digest

Federal Circuit Flas

By Kayla Haran – Edited by Ken Winterbottom Court Finds Negative ...

Fed. Cir. Flash Digest

Federal Circuit Flas

By Patrick Gallagher – Edited by Ken Winterbottom TOR Project Head ...


Senate passes Cybers

Senate passes Cybersecurity Information Sharing Act By Frederick Ding — Edited by ...

Senate Judiciary Committee

Senators push bill p

By Bhargav Srinivasan – Edited by Olga Slobodyanyuk In October, Senators ...


Federal Circuit Flas

Federal Circuit Flash Digest By Keke Wu – Edited by Yunnan ...